Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an effic ...

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

The clinical-stage biopharmaceutical company said the Phase 3 study didn't demonstrate a statistically significant improvement on the primary endpoint of change from baseline in a scale that measures ...

DRIVING under the influence of drink or drugs, including prescription drugs, is usually to blame for cases of dangerous ...

NRx Pharma files initial section of NDA to US FDA for NRX-100 to treat suicidal depression: Wilmington, Delaware Tuesday, December 31, 2024, 17:00 Hrs [IST] NRx Pharmaceuticals, I ...

SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...